stockrowScilex Holding Company
SCLXHealthcare Drug Manufacturers General
Scilex Holding Company’s revenue for fiscal 2025 (year ended December 2025) was $30.3 million, down 46.5% from fiscal 2024.
- Revenue
- −22.8%
- EPS
- −124.4%
- Free cash flow
- −203.8%
- Total debt
- +102.7%
Quarter to June 2026, against a year earlier
Follow SCLX
Alert me
Scilex Holding Company (SCLX) EV/Sales
As of 6 November 2026, Scilex Holding Company (SCLX) trades at a EV/Sales of 2.9×. Over the past ten years it has ranged from 0.0× (December 2022) to 40.5× (April 2023); the current reading is higher than 38% of that period. That is below the Drug Manufacturers General industry median of 4.1× and below the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 6.0× | 2.60% |
| FY2024 | 5.8× | 1.61% |
| FY2023 | 5.7× | (62.11%) |
| FY2022 | 15.2× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 4.3× | 25.53% |
| Mar 2026 | 3.4× | (43.25%) |
| Dec 2025 | 6.0× | 5.59% |
| Sep 2025 | 5.7× | 174.26% |
| 14 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| AMRN Amarin Corporation PLC compare | −0.4× |
| MIRA MIRA Pharmaceuticals, Inc. compare | n/m |
| MDCX Medicus Pharma Ltd compare | n/m |
| NSRX Nasus Pharma Ltd. compare | n/m |
| OGN Organon & Co. compare | 1.8× |
| GRFS Grifols, S.A. compare | 1.8× |
| GSK GSK PLC Sponsored ADR compare | 2.9× |
| SCLX Scilex Holding Company | 2.9× |
| BIIB Biogen Inc. compare | 4.1× |
| Drug Manufacturers General industry median | 4.1× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)